In June 2021, semaglutide injection (once weekly, 2.4 mg), marketed as Wegovy, was approved by the FDA for the first time for the treatment of obesity
The final refinement yielded a map at overall 4.3 resolution
Research shows that most patients regain 50-75% of lost weight within one year of discontinuation, primarily because appetite hormones like ghrelin rebound to baseline levels
Before a patient has reached their ideal body weight or desired health goals, our focus should be on the journey, the here and now, and the hard work ahead to get the body of our dreams
The total effect is nevertheless meaningful (OR = 0.59,95% CI: 0.390.89, P = 0.0109), indicating that there is a significant causal association between GLP-1RA and DR risk reduction in the European population